Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to
control uveal melanoma.
Ipilimumab is designed to increase the immune system's ability to fight cancer.
Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow
the body's immune system to work against tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)